Sanofi adds SAR447537 (formerly INBRX-101) to its pipeline of therapies for rare conditions. SAR447537 is a human recombinant protein in development for the treatment of patients with alpha-1 antitrypsin deficiency (AATD).
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| The most anticipated drug approvals in 2024 | 5 | 53 | July 26, 2024 | |
| Inflation reduction act - prices negotiation | 2 | 33 | April 16, 2024 | |
| Health Economic Modelling in NASH | 0 | 28 | April 2, 2024 | |
| G-BA requirements for COAs | 4 | 29 | April 28, 2024 | |
| Educational Resources on Market Access and Health Economics | 3 | 37 | June 14, 2024 |